Immunocore Holdings plc Cost of Revenue
Immunocore Holdings plc (IMCR) reported Cost of Revenue of $1.09 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement
us-gaap:CostOfRevenue · last filed 2026-08-06
- Immunocore Holdings plc cost of revenue for the quarter ending 2026-06-30 was $1.09M, a 4.62% increase year-over-year.
- Immunocore Holdings plc cost of revenue for the quarter ending 2026-03-31 was $434.00K, a 47.77% decline year-over-year.
- Immunocore Holdings plc cost of revenue for the quarter ending 2025-12-31 was $2.70M, a 719.09% increase year-over-year.
- Immunocore Holdings plc cost of revenue for the quarter ending 2025-09-30 was $513.00K, a 14.51% increase year-over-year.
- Immunocore Holdings plc cost of revenue for fiscal 2025 was $5.09M, a 86.27% increase from fiscal 2024.
- Immunocore Holdings plc cost of revenue for fiscal 2024 was $2.73M, a 163.36% increase from fiscal 2023.
- Immunocore Holdings plc cost of revenue for fiscal 2023 was $1.04M, a 4.78% decline from fiscal 2022.
- Immunocore Holdings plc cost of revenue for fiscal 2022 was $1.09M.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month | Cost of Revenue 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.09M 10-Q · filed 2026-08-06 | $1.52M 10-Q · filed 2026-08-06 | $4.22M derived: sum of 3 quarters · filed 2026-08-06 | $4.74M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $434.00K 10-Q · filed 2026-05-06 | $3.14M derived: sum of 2 quarters · filed 2026-05-06 | $3.65M derived: sum of 3 quarters · filed 2026-05-06 | $4.69M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $2.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $3.22M derived: sum of 2 quarters · filed 2026-02-25 | $4.26M derived: sum of 3 quarters · filed 2026-08-06 | $5.09M 10-K · filed 2026-02-25 |
| 2025-09-30 | $513.00K 10-Q · filed 2025-11-06 | $1.55M derived: sum of 2 quarters · filed 2026-08-06 | $2.38M 10-Q · filed 2025-11-06 | $2.71M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.04M 10-Q · filed 2026-08-06 | $1.87M 10-Q · filed 2026-08-06 | $2.20M derived: sum of 3 quarters · filed 2026-08-06 | $2.65M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $831.00K 10-Q · filed 2026-05-06 | $1.16M derived: sum of 2 quarters · filed 2026-05-06 | $1.61M derived: sum of 3 quarters · filed 2026-05-06 | $3.32M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $330.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $778.00K derived: sum of 2 quarters · filed 2026-02-25 | $2.48M derived: sum of 3 quarters · filed 2026-02-25 | $2.73M 10-K · filed 2026-02-25 |
| 2024-09-30 | $448.00K 10-Q · filed 2025-11-06 | $2.15M derived: sum of 2 quarters · filed 2025-11-06 | $2.40M 10-Q · filed 2025-11-06 | $2.60M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $1.71M 10-Q · filed 2025-08-07 | $1.95M 10-Q · filed 2025-08-07 | $2.15M derived: sum of 3 quarters · filed 2026-02-25 | $2.43M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $246.00K 10-Q · filed 2025-05-07 | $446.00K derived: sum of 2 quarters · filed 2026-02-25 | $722.00K derived: sum of 3 quarters · filed 2026-02-25 | $1.07M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $476.00K derived: sum of 2 quarters · filed 2026-02-25 | $822.00K derived: sum of 3 quarters · filed 2026-02-25 | $1.04M 10-K · filed 2026-02-25 |
| 2023-09-30 | $276.00K 10-Q · filed 2024-11-06 | $622.00K derived: sum of 2 quarters · filed 2024-11-06 | $837.00K 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $346.00K 10-Q · filed 2024-08-08 | $562.00K 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $216.00K 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | $1.09M 10-K · filed 2025-02-26 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |